{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:16:40Z","timestamp":1771010200877,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.amjcard.2014.03.046","type":"journal-article","created":{"date-parts":[[2014,4,3]],"date-time":"2014-04-03T05:02:21Z","timestamp":1396501341000},"page":"2018-2020","source":"Crossref","is-referenced-by-count":35,"title":["Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials"],"prefix":"10.1016","volume":"113","author":[{"given":"Sripal","family":"Bangalore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Fayyad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Laskey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liffert","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"DeMicco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2014.03.046_bib1","doi-asserted-by":"crossref","first-page":"f880","DOI":"10.1136\/bmj.f880","article-title":"Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases","volume":"346","author":"Dormuth","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2014.03.046_bib2","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2014.03.046_bib3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2014.03.046_bib4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2014.03.046_bib5","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2014.03.046_bib6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2014.03.046_bib7","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2014.03.046_bib8","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2014.03.046_bib9","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2014.03.046_bib10","series-title":"The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome","author":"Sarma","year":"2013"},{"key":"10.1016\/j.amjcard.2014.03.046_bib11","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2014.03.046_bib12","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.amjmed.2012.06.021","article-title":"Preoperative statin use and postoperative acute kidney injury","volume":"125","author":"Brunelli","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2014.03.046_bib13","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.amjcard.2012.02.019","article-title":"Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study)","volume":"109","author":"Ho","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2014.03.046_bib14","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study","volume":"51","author":"Shepherd","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914914008893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914914008893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T05:51:03Z","timestamp":1538718663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914914008893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0002914914008893"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2014.03.046","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}